Literature DB >> 6723755

The effect of oral administration of dipyrone on the capacity of blood platelets to synthesize thromboxane A2 in man.

A Eldor, E Zylber-Katz, M Levy.   

Abstract

Platelet aggregation and thromboxane A2 (TXA2) production induced by arachidonic acid and collagen were studied in 10 healthy volunteers prior to and at various times after the oral administration of a single dose of 1 g dipyrone. The plasma concentrations of four dipyrone metabolites were also determined. Dipyrone inhibited platelet aggregation and markedly decreased TXA2 synthesis induced by threshold concentrations of both agonists. Maximal inhibition was noted 1 hour after drug administration and in some subjects it lasted as long as 72 h. At all times the effect of the drug could be abolished by increasing the concentration of the agonist. This is consistant with a competitive inhibitory effect of dipyrone on prostaglandin synthetase activity. The mean plasma concentration of the main dipyrone metabolite methylaminoantipyrine at 1 h was 11 micrograms/ml. There was no correlation between individual plasma levels and the parameters of platelet function. At 24h the mean concentration of each of the metabolites studied was up to 1 microgram/ml, and these levels, too, did not correlate with the biological effect of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723755     DOI: 10.1007/BF00630282

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone.

Authors:  A Kaegi; G F Pineo; A Shimizu; H Trivedi; J Hirsh; M Gent
Journal:  N Engl J Med       Date:  1974-02-07       Impact factor: 91.245

2.  Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy.

Authors:  H S Weily; E Genton
Journal:  Circulation       Date:  1970-11       Impact factor: 29.690

3.  Platelet-suppressant therapy in patients with coronary artery disease.

Authors:  P Steele; J Rainwater; R Vogel; E Genton
Journal:  JAMA       Date:  1978-07-21       Impact factor: 56.272

Review 4.  10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts).

Authors:  V Fuster; J H Chesebro
Journal:  Mayo Clin Proc       Date:  1981-03       Impact factor: 7.616

5.  Drugs which inhibit prostaglandin biosynthesis.

Authors:  R J Flower
Journal:  Pharmacol Rev       Date:  1974-03       Impact factor: 25.468

6.  Acetylation of prostaglandin synthase by aspirin.

Authors:  G J Roth; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

7.  Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

Review 8.  Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone).

Authors:  M Volz; H M Kellner
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

9.  Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells.

Authors:  R I Levin; E A Jaffe; B B Weksler; K Tack-Goldman
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

10.  Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin.

Authors:  M Ali; J W McDonald
Journal:  J Lab Clin Med       Date:  1977-04
View more
  10 in total

1.  The opiate-sparing effect of dipyrone in post-operative pain therapy with morphine using a patient-controlled analgesic system.

Authors:  G Tempel; B von Hundelshausen; W Reeker
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

2.  [Analgesics in general practice].

Authors:  W Forth
Journal:  Klin Wochenschr       Date:  1986-03-17

3.  Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity.

Authors:  Christian Pfrepper; Carolin Dietze; Yvonne Remane; Thilo Bertsche; Susanne Schiek; Thorsten Kaiser; Ines Gockel; Christoph Josten; Sirak Petros
Journal:  Eur J Clin Pharmacol       Date:  2020-01-08       Impact factor: 2.953

4.  Inhibition of cyclooxygenases by dipyrone.

Authors:  S C Pierre; R Schmidt; C Brenneis; M Michaelis; G Geisslinger; K Scholich
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

5.  Metamizole-furosemide interaction study in healthy volunteers.

Authors:  B Rosenkranz; K H Lehr; G Mackert; H W Seyberth
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 8.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Pharmacokinetics of metamizole (dipyrone) as an add-on in calves undergoing umbilical surgery.

Authors:  Daniela Fux; Moritz Metzner; Johanna Brandl; Melanie Feist; Magdalena Behrendt-Wippermann; Anne von Thaden; Christine Baumgartner
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

10.  Lack of influence of the COX inhibitors metamizol and diclofenac on platelet GPIIb/IIIa and P-selectin expression in vitro.

Authors:  Dirk Scheinichen; Holger-Andreas Elsner; Rodin Osorio; Björn Jüttner; Werner Gröschel; Karsten Jaeger; Siegfried Piepenbrock
Journal:  BMC Anesthesiol       Date:  2004-04-23       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.